September 25-26, 2014 Valencia, Spain

Tentative Scientific Program

	Day 1	
	25-09-2014	
08:00-09:00	Registrations	
09:00-09:30	Opening Ceremony	
Keynote Forum		
09:30-09:35	Introduction	
09:35-10:00	Title: Current directions for process validation according FDA and EMA	
	Victor Sanchez, Pharma-Bio Serv, S.L., Spain	
10:00-10:25	Title: Planning to outsource manufacturing: Have you done your homework?	
	Mohammed R Khan, Synergex Consulting, Canada	
10:25-10:50	Title: Essentials in Quality by Design	
	Thomas A. Little, Thomas A. Little Consulting, USA	
10:50-11:05	Networking and Refreshment Break	
11.05 11.20	Title: <i>In-Vitro</i> release testing and IVIVC of complex parenteral products	
11:05-11:30	Diane J. Burgess, University of Connecticut, USA	
	Track 1: Good Manufacturing Practices: The Gap within Track 2: Current Regulations and Ouality Standards	
	Track 1: Good Manufacturing Practices: The Gap within Track 2: Current Regulations and Quality Standards Track 3: Current GMP Guidelines	
	Track 2: Current Regulations and Quality Standards	
	Track 2: Current Regulations and Quality Standards Track 3: Current GMP Guidelines Session Introduction	
11:30-11:50	Track 2: Current Regulations and Quality Standards Track 3: Current GMP Guidelines	
11:30-11:50	Track 2: Current Regulations and Quality Standards Track 3: Current GMP Guidelines Session Introduction Title: Regulatory requirements and benefits converting to continued process	
	Track 2: Current Regulations and Quality Standards Track 3: Current GMP Guidelines Session Introduction Title: Regulatory requirements and benefits converting to continued process verification	
11:30-11:50 11:50-12:10	Track 2: Current Regulations and Quality Standards Track 3: Current GMP Guidelines Session Introduction Title: Regulatory requirements and benefits converting to continued process verification Magnus Jahnsson, Pharmadule Morimatsu AB, Sweden	
	Track 2: Current Regulations and Quality Standards Track 3: Current GMP Guidelines Session Introduction Title: Regulatory requirements and benefits converting to continued process verification Magnus Jahnsson, Pharmadule Morimatsu AB, Sweden Title: Quality excellence through benchmarking quality improvement models	

12:30-12:50	Title: Effective methods for software and systems integration for software companies and institutions	
12:50-13:10	Boyd L. Summers, BL Summers Consulting LLC., USA	
	Title: From a training perspective: What does the FDA look for during an inspection?	
	David Gallup, Training and Communications Group, Inc., USA	
	Speaker Opportunity Available	
13:10-14:00	Lunch Break	
Track 4: The Role of "C" in cGMP Track 5: Good Clinical Practices & Good Laboratory Practices		
14:00-14:20	Workshop: "Natural health products site licensing in Canada: How to meet the GMPs regulations"	
	Jalal Mokhalalati, QMRS, Canada	
14:20-14:40	Title: GMP compliance for inspections, sampling and testing of packaging components in pharmaceuticals	
14:40-15:00	Sarma R Donepudi, SCITECHSOLUTIONS Inc., Canada	
	Title: Industrial process validation of metformin tablets to facilitate the scale up of commercial production: A GMP and validation perspective	
	Gannu Praveen Kumar, Sahasra Institute of Pharmaceutical Sciences, India	
15:00-15:20	Title: The regulatory inspection & audits	
15,00-15,20	Neeraj Srivastava, Consultant, India	
15:20-15:40	Title: Greening the pharmaceutical industry to afford good laboratory practice	
15:20-15:40	Salwa Elmeligie, Cairo University, Egypt	
	Speaker Opportunity Available	
15:40-16:00	Networking and Refreshment Break	
16:00-16:20	Title: Reflections about quality control and quality assurance in clinical trials	
10.00 10.20	Fernando Geijo, Azbil Telstar, Spain	
16:20-16:40	Title: A guide to an effective clinical trial protocol in CGMP & CGCP as a tool for sustenance of ethical principles and regulatory requirements in the pharmaceutical and	
	Peter Odeh, SNBL Clinical Pharmacology Center, USA	
16:40-17:00	Title: Role of Good Laboratory Practice in Good Clinical Practice	
	Salwa Elmeligie, Cairo University, Egypt	
	Speaker Opportunity Available	
	Panel Discussion	

	Day 2
	26-09-2014
	Track 6: Quality Assurance Track 7: Quality Control Track 8: Validation
	Session Introduction
09:00-09:20	Title: Analytical method development and validation for therapeutic proteins
	Robert Zoubek, Granzer Regulatory Consulting & Services, Germany
09:20-09:40	Title: Analytical method lifecycle management
07.20-07.40	Gerald de Fontenay, Amatsi Group, France
09:40-10:00	Title: Application of a risk analysis method to different technologies for producing a monoclonal antibody employed in Hepatitis B vaccine manufacturing
	Lorely Haidee, Center for Genetic Engineering and Biotechnology, Cuba
10:00-10:20	Title: Quality control and lean management: A holistic concept of building quality and cost reduction in a manufacturing enterprise
	Akintunde A. Sowunmi, Manufacturing engineer at Olympus KeyMed, UK
10:20-10:40	Title: A risk based scientific approach to analytical method development and validation activities for regulated laboratories
	Alicia Tebar, Project manager QA & QbD en Azbil Telstar, Spain
10:40-11:00	Networking and Refreshment Break
11:00-11:20	Title: Toxicological assessment of degradation products: Is it relevant as a complementary approach during stability testing of pharmaceuticals?
	Daniele Rubert Nogueira, Universidade Federal de Santa Maria, Spain
11:20-11:40	Title: Evaluation of bacterial contamination of clean room clothing
	Noëlle H. O'Driscoll, Robert Gordon University, Scotland
11:40-12:00	Title: Optimization solutions for validation procedures in the quality control of enantiomers chirality tests for antidepressants Citalopram and Venlafaxine
	Ivanka Pencheva, Medical University – Sofia, Bulgaria
12:00-12:20	Title: Quality by design for complex parenteral products
	Diane J. Burgess, University of Connecticut, USA
12:20-12:40	Title: Comparative evaluation of biomarker Psoralen in antioxidant active extracts of different species of genus Ficus by validated HPTLC method
	Perwez Alam, King Saud University, Saudi Arabia

12:40-13:00	Title: Pharmaceutical quality system	
	Lothar Hartmann, Crucell, Switzerland	
	Speaker Opportunity Available	
13:00-13:40	Lunch Break	
Track 09: Contract Manufacturing, Sterile/Aseptic Manufacturing Track 10: GMP in Microbiology, Biotechnology and Food Industry		
13:40-14:40	Workshop: Best practices for internal and supplier auditing David L. Chesney, PAREXEL International, USA	
14:40-15:00	Title: DHF, DMR and DHR – the three Ds of medical devices	
15:00-15:20	Rama K Pidaparti, Wipro Technologies, USA Title: Maintain the effectiveness of a QMS by using lean six sigma approach Peter Jehander, ÅF Technology AB, Sweden	
15:20-15:40	Title: Good distribution practices Javier Franch, Warehouse & Distribution EMEA at Edwards Life sciences, Spain	
15:40-16:00	Title: GMP system implementation and certification to manufacture seawater ampoules as a dietary supplement under ISO 5 air quality	
16:00-16:20	María Pellín Amorós, Quinton International, Spain Title: Assessing pharmaceutical equipment containment using surrogate monitoring (SMEPAC)	
16:20-16:40	Mootaz El Halawani, Pharmaceutical Quality Expert, Egypt Title: Sterile/Aseptic manufacturing: Additional challenges in production of radiopharmaceuticals	
	Valentina Ferrari, GE Healthcare, UK	
16:40-17:00	Title: Ensure Quality Assurance for Software Companies and Institutions Boyd L. Summers, BL Summers Consulting LLC., USA	
	Speaker Opportunity Available	
Track 11:Medical Devices Track 12:Computational Strategies in GMP/GCP Track 13:Storage, Distribution, Transportation		
	Speaker Opportunity Available Speaker Opportunity Available Speaker Opportunity Available	
Speaker Opportunity Available Breakout 2 Poster Presentations		
B2B Editorial Board Meeting		

Please note that this is a tentative program. Timings in this program may subject to change

Workshop on

Natural Health Products site licensing in Canada: How to meet the GMPs regulations

bv



Dr. Jalal Mokhalalati
Principal, Quality Medical Regulations Services

Workshop on

Best Practices for Internal and Supplier Auditing

by

David L. Chesney

Vice President and Practice Lead Strategic Compliance Services PAREXEL Consulting



